Home » Newsletters » BioWorld Science

BioWorld Science

April 14, 2020

View Archived Issues

Dual mu-opioid/nociceptin receptor agonist BPR-1M97 shows advantages over morphine

Death, taxes and zoonotic spillover

Phase I trial of INO-5150 immunotherapy against PSA/PSMA in biochemically relapsed prostate cancer

An innovative 3D fiber-reinforced hydrogel for the regeneration of corneal stroma

Exosomes deliver sepsis treatment

Dopamine has epigenetic role in addiction

Koselugo receives FDA approval for pediatric patients with NF1-related plexiform neurofibromas

Metacrine patents farnesoid X receptor agonists

SOX4-dependent regulation of a subset of tRNA genes controls human glioblastoma cell proliferation

New melanocortin MC4 receptor agonists identified at Palatin Technologies

Bristol-Myers Squibb discovers lysophosphatidic acid receptor 1 antagonists

Loss-of-function mutation in BK channel reduces mitochondrial viability, causing progressive ataxia

Phase III study of tislelizumab plus chemotherapy in NSCLC meets primary endpoint

Roche, Genentech describe new MAP4K1 inhibitors

FDA lifts clinical hold on phase III study of TG-C

New small-molecule inhibitor of enterovirus 71 for the treatment of hand, foot and mouth disease

Goldfinch Biopharma presents new TRPC5/TRPC4 antagonists

Potent and selective sphingosine kinase 2 inhibitor targeting a small side cavity

Ridgeback Biotherapeutics initiates phase I study of EIDD-2801 for COVID-19

PLOD1 mutation tied to smooth muscle cell dysfunction and aortopathy

Bausch Health initiates clinical trial of Virazole in patients with COVID-19

BioInvent reports early responses in phase I/IIa study of BI-1206 for NHL

AstraZeneca to unblind phase III ADAURA trial of Tagrisso early based on efficacy

Lilly advances plans to evaluate baricitinib and LY-3127804 for COVID-19

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...